REFRACTORY METASTATIC COLORECTAL CANCER
Clinical trials for REFRACTORY METASTATIC COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY METASTATIC COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for REFRACTORY METASTATIC COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat colorectal cancer: drug targets specific protein
Disease control OngoingThis phase 3 trial tests two different doses of an investigational drug called telisotuzumab adizutecan in about 74 adults with metastatic colorectal cancer that has stopped responding to standard treatments and whose tumors have a specific protein (c-Met). The drug is given by I…
Matched conditions: REFRACTORY METASTATIC COLORECTAL CANCER
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy offers hope for hard-to-treat GI cancers
Disease control OngoingThis study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…
Matched conditions: REFRACTORY METASTATIC COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rottapharm Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC